文献速递血栓与止血浆细胞疾病

SAVED评分在接受免疫调节药物治疗的多发性骨髓瘤患者静脉血栓栓塞风险分层中的外部验证

External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs.
PubMed 文献 · Br J Haematol · 2023-01-05

该研究利用2010至2019年间501例新开始免疫调节药物治疗的多发性骨髓瘤患者的回顾性数据,首次对SAVED评分进行独立外部验证。结果显示,高危组开始免疫调节药物治疗后6个月和12个月静脉血栓栓塞累积发生率分别为32%和42%,低危组分别为6%和9%;SAVED评分预测12个月内静脉血栓栓塞的C统计量为0.74(95%CI:0.69-0.78),优于其他几种多发性骨髓瘤静脉血栓栓塞风险模型。

要点

  • 高危组开始免疫调节药物治疗后6个月和12个月静脉血栓栓塞累积发生率分别为32%和42%,低危组分别为6%和9%。
  • SAVED评分预测12个月内静脉血栓栓塞的C统计量为0.74(95%CI:0.69-0.78)。
  • SAVED评分优于其他几种多发性骨髓瘤静脉血栓栓塞风险模型。

核心结论

  • SAVED评分是用于开始含免疫调节药物方案患者静脉血栓栓塞分层的准确风险评估工具。

研究设计与样本

  • 回顾性数据来自2010至2019年间501例新开始免疫调节药物治疗的多发性骨髓瘤患者,为SAVED评分的首次独立外部验证。

主要发现

  • 高危组开始免疫调节药物治疗后6个月和12个月静脉血栓栓塞累积发生率分别为32%和42%,低危组分别为6%和9%。
  • SAVED评分预测12个月内静脉血栓栓塞的C统计量为0.74(95%CI:0.69-0.78),优于其他几种多发性骨髓瘤静脉血栓栓塞风险模型。

关键数值与推荐

  • SAVED评分预测12个月内静脉血栓栓塞的C统计量为0.74(95%CI:0.69-0.78)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Selective patients with multiple myeloma (MM) receiving immunomodulatory drugs (IMiD) are at high risk for venous thromboembolism (VTE). The SAVED score is a VTE risk prediction model recently incorporated into the National Comprehensive Cancer Network (NCCN) guidelines. Using retrospective data from 501 MM patients with new IMiD initiation between 2010 and 2019, we performed the first independent external validation of this model. The cumulative incidence of VTE after IMiD initiation at 6 and 12 months was 32% and 42% in the high-risk group, versus 6% and 9% in the low-risk group respectively. The C-statistic of the SAVED score to predict VTE within 12 months of IMiD-based treatment start was 0.74 [95% confidence interval (CI): 0.69-0.78], which outperformed several other VTE risk models in MM patients. Our findings suggest that the SAVED score is an accurate risk assessment tool for VTE stratification in patients initiating IMiD-containing regimens.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Dima D, Li A, Granat LM, et al. External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs. Br J Haematol. 2023. PMID: 36604838. doi:10.1111/bjh.18630

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。